{"id":"W4384520841","doi":"10.1200/jco.22.02760","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Chemotherapy; Placebo; Capecitabine; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002385921,0.001396155,0.003552983,0.0005452862,0.0003710026,0.00121681,0.0009522244,0.001612481,0.003263533],"category_scores_gemma":[0.001804532,0.0007422256,0.001498511,0.0006413559,0.001052817,0.0007638482,0.0003721075,0.002236001,0.0006342672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001078153,"about_ca_system_score_gemma":0.001596642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000924804,"about_ca_topic_score_gemma":0.002890087,"domain_scores_codex":[0.9989074,0.0006687189,0.00005372516,0.0001411272,0.0001040093,0.0001250654],"domain_scores_gemma":[0.9990008,0.0002104952,0.0002597339,0.00006929014,0.00007153801,0.000388063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9325966,0.02174859,0.001129427,0.0009312095,0.001478687,0.00008433691,0.00004715997,0.0006222131,0.007183388,0.0001002959,0.0009981145,0.03308003],"study_design_scores_gemma":[0.8866789,0.1102995,0.001156179,0.00003173367,0.0004043467,0.00003953736,0.00000805206,0.0004112721,0.0003432598,0.00005773824,0.0005599892,0.000009657406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798666,0.009489913,0.001126071,0.0007757593,0.0006614347,0.005690438,0.0007009408,0.0001417214,0.001546998],"genre_scores_gemma":[0.978735,0.006542414,0.002748481,0.001322731,0.0008459035,0.006767683,0.00102855,0.00003471546,0.001974589],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003552983,"threshold_uncertainty_score":0.01261806,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1009913211866394,"score_gpt":0.4850312222814466,"score_spread":0.3840399010948072,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}